Repurposing statins for treatment of Klebsiella pneumoniae infections: in vitro and in vivo study

Pharmacology, Toxicology and Pharmaceutical Science

1. Acinetobacter Baumannii 5%
2. Agar 5%
3. Antibacterial Activity 15%
4. Antibiotic Resistance 31%
5. Antibiotics 63%
6. Antiinfective Agent 73%
7. Antiinflammatory Agent 5%
8. Antimicrobial Agent 5%
9. Antimicrobial Susceptibility Test 5%
10. Antipsychotic 5%
11. Atorvastatin 5%
12. Bacterial Infection 21%
13. Bloodstream Infection 5%
14. Chitosan 5%
15. Chronic Disease 5%
16. Colistimethate 5%
17. Community Acquired Infection 5%
18. Diseases 21%
19. Drug Repositioning 26%
20. Drug Resistance 15%
21. Electron Microscopy 5%
22. Enterobacteriaceae 5%
23. Extended Spectrum Beta Lactamase 5%
24. Gram Negative Bacterium 5%
25. Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 100%
26. Imipenem 5%
27. Immunocompromised Patient 5%
28. Infection 63%
29. Infectious Agent 21%
30. Klebsiella pneumoniae 100%
31. Klebsiella Pneumoniae Infection 100%
32. Lactic Acid Bacterium 5%
33. Microorganism 5%
34. Non-Steroidal Anti-Inflammatory Drug 5%
35. Pathogenicity 5%
36. Prevalence 5%
37. Repurposing 100%
38. Respiratory Tract Infection 5%
39. Rosuvastatin 5%
40. Scanning Electron Microscopy 5%
41. Simvastatin 5%
42. Statin (Protein) 10%
43. Structure Activity Relationship 5%
44. Surgical Infection 5%
45. Urinary Tract Infection 5%